Stock Research for LGND


Featured Broker: Ally Invest

Get the due diligence for another stock.


LGND Stock Chart & Research Data

The LGND chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the LGND chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.


LGND Due diligence Resources & Stock Charts

The LGND stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.

The Four Most Popular Resources

CNN View LGND Detailed Price Forecast - CNN Money CNN View LGND Detailed Summary - Google Finance
Yahoo View LGND Detailed Summary - Yahoo! Finance Zacks View LGND Stock Research & Analysis -

Stock Analysis

TradeIdeas View LGND Trends & Analysis - Trade-Ideas Barrons View LGND Major Holders - Barrons
NASDAQ View LGND Call Transcripts - NASDAQ Seeking View LGND Breaking News & Analysis - Seeking Alpha
Spotlight View LGND Annual Report - OTC Report View LGND OTC Short Report -
TradeKing View LGND Fundamentals - TradeKing Charts View LGND SEC Filings - Bar Chart
WSJ View Historical Prices for LGND - The WSJ Morningstar View Performance/Total Return for LGND - Morningstar
MarketWatch View the Analyst Estimates for LGND - MarketWatch CNBC View the Earnings History for LGND - CNBC
StockMarketWatch View the LGND Earnings - StockMarketWatch MacroAxis View LGND Buy or Sell Recommendations - MacroAxis
Bullish View the LGND Bullish Patterns - American Bulls Short Pains View LGND Short Pain Metrics -

Social Media Mentions

StockTwits View LGND Stock Mentions - StockTwits PennyStocks View LGND Stock Mentions - PennyStockTweets
Twitter View LGND Stock Mentions - Twitter Invest Hub View LGND Investment Forum News - Investor Hub
Yahoo View LGND Stock Mentions - Yahoo! Message Board Seeking Alpha View LGND Stock Mentions - Seeking Alpha

Financial & Transaction Holdings

SECform4 View Insider Transactions for LGND - Insider Cow View Insider Transactions for LGND - Insider Cow
CNBC View LGND Major Holdings Summary - CNBC OTC Markets View Insider Disclosure for LGND - OTC Markets
Yahoo View Insider Transactions for LGND - Yahoo! Finance NASDAQ View Institutional Holdings for LGND - NASDAQ

Stock Charts

FinViz View LGND Stock Insight & Charts - StockCharts View LGND Investment Charts -
BarChart View LGND Stock Overview & Charts - BarChart Trading View View LGND User Generated Charts - Trading View

Latest Financial News for LGND

See what the IHS Markit Score report has to say about Ligand Pharmaceuticals Inc.
Posted on Thursday December 13, 2018

Ligand Pharmaceuticals Inc NASDAQ NMS:LGND

Ligand Pharmaceuticals Inc. (LGND) Hedge Funds Are Snapping Up
Posted on Wednesday December 12, 2018

Is Ligand Pharmaceuticals Inc. (NASDAQ:LGND) a good stock to buy right now? We at Insider Monkey like to examine what billionaires and hedge funds think of a company before doing days of research on it. Given their 2 and 20 payment structure, hedge funds have more resources than the average investor. The funds have access […]

Sermonix Announces FDA Acceptance of IND Application; Will Begin Phase 2 Trial of Lasofoxifene for Targeted Treatment of Women With ESR1 Mutations in Metastatic Breast Cancer
Posted on Monday December 10, 2018

Sermonix Pharmaceuticals LLC, a privately held biopharmaceutical company focused on the development and commercialization of female-specific oncology products, today announced that the U.S. Food and Drug Administration (FDA) accepted the company’s Investigational New Drug (IND) application, indicating that Sermonix may proceed directly to a Phase 2 clinical study in the personalized medicine arena involving its lead investigational drug, lasofoxifene. The open-label, randomized, multi-center study is expected to begin enrollment in early 2019 and will evaluate the activity of oral lasofoxifene versus intramuscular fulvestrant for the treatment of postmenopausal women with locally advanced or metastatic estrogen receptor-positive (ER+)/HER2- breast cancer with an ESR1 mutation.

Why Is Ligand (LGND) Down 14.9% Since Last Earnings Report?
Posted on Saturday December 08, 2018

Ligand (LGND) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Stock Market & Investing Books

Enter a stock symbol to view the stock details.